Table 4.
Associations of statins use with late-stage breast cancer by ER status
| ER status | Comparison | Model type | HR | 95 % CI | p value |
|---|---|---|---|---|---|
| ER positive | Baseline statin: yes versus no | Univariable | 0.80 | (0.63, 1.01) | 0.062 |
| Multivariablea | 0.85 | (0.67, 1.08) | 0.191 | ||
| Baseline statin: by typeb | Univariable | ||||
| Lipophilic versus none | 0.79 | (0.60, 1.03) | 0.080 | ||
| Hydrophilic versus none | 0.85 | (0.53, 1.35) | 0.484 | ||
| Lipophilic versus hydrophilic | Multivariable | 0.93 | (0.55, 1.58) | 0.783 | |
| Lipophilic versus none | 0.85 | (0.65, 1.12) | 0.244 | ||
| Hydrophilic versus none | 0.85 | (0.52, 1.40) | 0.521 | ||
| Lipophilic versus hydrophilic | 1.00 | (0.57, 1.74) | 0.998 | ||
| Statin use over time: yes versus no | Univariable | 0.78 | (0.63, 0.96) | 0.018 | |
| Multivariable | 0.79 | (0.63, 0.99) | 0.044 | ||
| Statin use over time: by typeb | Univariable | ||||
| Lipophilic versus none | 0.73 | (0.58, 0.92) | 0.009 | ||
| Hydrophilic versus none | 0.87 | (0.54, 1.41) | 0.549 | ||
| Lipophilic versus hydrophilic | Multivariablea | 0.84 | (0.50, 1.42) | 0.511 | |
| Lipophilic versus none | 0.72 | (0.56, 0.93) | 0.012 | ||
| Hydrophilic versus none | 1.01 | (0.62, 1.63) | 0.978 | ||
| Lipophilic versus hydrophilic | 0.72 | (0.42, 1.22) | 0.218 | ||
| ER negative/borderline | Baseline statin: yes versus no | Univariable | 1.15 | (0.74, 1.78) | 0.536 |
| Multivariablea | 1.29 | (0.82, 2.02) | 0.266 | ||
| Baseline statin: by typeb | Univariable | ||||
| Lipophilic versus none | 1.08 | (0.65, 1.80) | 0.763 | ||
| Hydrophilic versus none | 1.38 | (0.61, 3.11) | 0.436 | ||
| Lipophilic versus hydrophilic | Multivariable | 0.78 | (0.31, 2.00) | 0.609 | |
| Lipophilic versus none | 1.21 | (0.72, 2.03) | 0.468 | ||
| Hydrophilic versus none | 1.56 | (0.69, 3.53) | 0.287 | ||
| Lipophilic versus hydrophilic | 0.78 | (0.30, 1.99) | 0.598 | ||
| Statin use over time: yes versus no | Univariable | 0.98 | (0.65, 1.48) | 0.911 | |
| Multivariable | 0.96 | (0.61, 1.51) | 0.848 | ||
| Statin use over time: by typeb | Univariable | ||||
| Lipophilic versus none | 0.96 | (0.61, 1.52) | 0.870 | ||
| Hydrophilic versus none | 1.46 | (0.64, 3.30) | 0.366 | ||
| Lipophilic versus hydrophilic | Multivariablea | 0.66 | (0.27, 1.63) | 0.368 | |
| Lipophilic versus none | 0.96 | (0.59, 1.58) | 0.877 | ||
| Hydrophilic versus none | 1.39 | (0.56, 3.40) | 0.478 | ||
| Lipophilic versus hydrophilic | 0.69 | (0.26, 1.86) | 0.469 |
Adjusted for race (American Indian or Alaskan Native; Asian or Pacific Islander; Black or African–American; Hispanic/Latino; White), education (none to some HS; HS diploma/GED; vocational, training school, some college or associate degree; college degree or more), smoking (never smoked; past smoker; current smoker), BMI (<25; 25–29; ≥30), waist circumference (≤88 cm;>88 cm), mammogram in the past 2 years (no; yes), Gail 5-year risk (<1.67 %; ≥1.67 %), female relative with breast cancer(no; yes), age at menarche (≤11, 12–13; 14+), number of live births (never pregnant; none; 1–2; 3+), breast biopsy (no; yes), hysterectomy (no; yes), hormone use (never; past user; current user <5 years; current user 5 to <10 years; current user ≥10 years), oral contraceptive (no; yes), aspirin use (no; yes) and study component (observational study; estrogen alone clinical trial, estrogen + progesterone clinical trial; dietary modification clinical trial; estrogen/estrogen + progesterone and dietary modification clinical trial)
Lipophilic (lovastatin, simvastatin, fluvastatin, atorvastatin), hydrophilic (pravastatin)